In recent years, the registration of "China's first class new drugs"

Since the national drug audit reform was launched in 2015, the design of relevant reform systems and the intensive release of supporting policies have opened the door for innovation in China's pharmaceutical industry The State encourages the research and development of new drugs, which will play an increasingly important role in the development of Chinese pharmaceutical enterprises According to the query of yaodu.com, as of May 14, 2018, there have been 891 first-class new drugs in China, involving tumor, cardiovascular, nervous system, infectious diseases and many other fields, which can be described as blooming In terms of drug classification, R & D stage and clinical status (including listing, clinical application and clinical application), chemical drugs still play a leading role, accounting for 64% of the total R & D and 36% of biological drugs At present, there are few drugs on the market, accounting for only 6% of all drugs, mainly focusing on tumors, cardiovascular and cerebrovascular diseases and infectious diseases In addition, 7% of the drugs are in the market application stage (nda4%, bla3%), 26% of the drugs are in the clinical application stage, and 76% of the drugs are in the clinical stage Most of the drugs in the first phase were 55%, 13% and 8% respectively In terms of the drugs that have been used in clinic, 97% of the drugs are in normal clinical progress, 15% of the drugs are in no progress, and 3% of the drugs fail in clinical stage From the perspective of treatment field (including listing, clinical application, and clinical application), the field of first-class new drug treatment in China is most concerned about tumor, and its heat is much higher than other fields (see the figure below for details) In addition, infectious diseases, cardiovascular and cerebrovascular diseases, endocrine and metabolic diseases also have high fever At present, the top areas of the amount of drug used in hospitals are infectious diseases, digestive system and metabolism, blood system, anti-tumor, nerve, cardiovascular Due to the limited clinical efficacy, more adverse reactions and high price of anti-tumor drugs, the market is full of expectations, so in the development of new drugs, the heat of tumor is far greater than other fields At present, the market share of anti infective drugs is large Although the global market is shrinking and the domestic anti infective drugs are limited, the research and development of anti infective drugs will still be very hot in the short term Cardiovascular, cerebrovascular, endocrine and metabolic diseases in China have a large number of patients, the prevalence continues to rise and need long-term medication, also has a high R & D fever Small molecules still play a leading role in the research and development of tumor, cardiovascular and cerebrovascular diseases and endocrine and metabolic diseases in the hot research and development fields of new drugs in China; in infectious diseases, the number of chemical drugs and biological drugs is almost the same At present, the focus of global tumor research and development is still focused on targeted therapy, and tumor immunotherapy will become a trend In recent years, the development of biotechnology has led to the rapid development of biopharmaceutical research and development, while the heat of small molecule drugs has declined slightly In terms of R & D progress, most of the drugs are still in clinical phase I, far from the market At present, 51 new drugs have been applied for listing in China, involving tumor, cardiovascular and cerebrovascular diseases, infectivity and other aspects, including 31 drugs for NDA and 20 drugs for bla Since some drugs have no new progress at present, this table only lists the drugs in normal progress Summary with the rapid development of biological level, a more thorough understanding of the mechanism of tumor and other complex diseases, in recent years, the focus of drug research and development has gradually shifted from cardiovascular, antibacterial drugs to tumor, immune, nervous system and so on In recent years, biopharmaceutics have also begun to rise strongly, and their R & D speed has been accelerated In some fields, they have been able to compete with the number of chemical drugs For the research and development of large and popular tumors, breakthroughs and progress have been made continuously, and targeted drug therapy and immunotherapy have become a trend Reference: 1 Yaodu network database